SCHEMBL4128975

SCHEMBL4128975

Clc1ccc(C2(c3ccc(-c4ncnc5c4ncn5C4CCCCO4)cc3)CCNCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
TSHR P16473 1/20 0.52
CYP2C19 P33261 2/20 0.47
AKT1 P31749 2/20 0.46
AKT2 P31751 2/20 0.46
AKT3 Q9Y243 2/20 0.46
CYP3A4 P08684 1/20 0.46
PRKACA P17612 1/20 0.46
PRKACG P22612 1/20 0.46
PRKACB P22694 1/20 0.46
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
CYP2C9 P11712 1/20 0.44
NFKB1 P19838 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
APEX1 P27695 1/20 0.44
PI4KA P42356 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13651702 0.85 CYP1A2 (0.48) CYP1A2TSHRCYP2C19AKT1AKT2
SCHEMBL14391654 0.81 CYP1A2 (0.44) CYP1A2TSHRCYP2C19MEN1ALDH1A1
SCHEMBL4063885 0.81 CYP1A2 (0.56) CYP1A2TSHRCYP2C19AKT1AKT2
SCHEMBL4134543 0.76 CYP2C19 (0.57) CYP1A2TSHRCYP2C19MEN1ALDH1A1
SCHEMBL4068137 0.74 CYP1A2 (0.49) CYP1A2TSHRCYP2C19MEN1ALDH1A1
SCHEMBL4137893 0.73 CYP1A2 (0.54) CYP1A2TSHRCYP2C19AKT2MEN1
SCHEMBL4063305 0.72 CYP1A2 (0.53) CYP1A2TSHRCYP2C19MEN1ALDH1A1
SCHEMBL4122030 0.72 NPC1 (0.60) CYP1A2TSHRCYP2C19AKT2PRKACA
SCHEMBL4070092 0.72 NPC1 (0.54) CYP1A2TSHRCYP2C19AKT2MEN1
SCHEMBL22111670 0.72 CYP2C19 (0.52) CYP1A2TSHRCYP2C19CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253718-A1 Pharmaceutical Compounds GRK3, CNKSR1, CSNK1G3 CYP1A2 1220/4885TSHR 165/4885CYP2C19 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.